Which has preferable earnings & valuation, IMMP or SPRB?

Spruce Biosciences has lower revenue, but higher earnings than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 1.60 -$53.82M N/A N/A Spruce Biosciences $4.91M 23.59 -$38.97M -$39.78 N/A

Is IMMP or SPRB more profitable?

Prima BioMed's return on equity of 0.00% beat Spruce Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Spruce Biosciences N/A -123.53% -90.35%

Does the media refer more to IMMP or SPRB?

In the previous week, Spruce Biosciences had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Spruce Biosciences and 3 mentions for Prima BioMed. Spruce Biosciences' average media sentiment score of 1.21 beat Prima BioMed's score of 0.94 indicating that Spruce Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Spruce Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, CRBU or IMMP?

Prima BioMed has higher revenue and earnings than Caribou Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Caribou Biosciences $11.16M 4.52 -$148.12M -$1.08 N/A Prima BioMed $16.40M 1.60 -$53.82M N/A N/A

Does the media prefer CRBU or IMMP?

In the previous week, Caribou Biosciences had 27 more articles in the media than Prima BioMed. MarketBeat recorded 30 mentions for Caribou Biosciences and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.94 beat Caribou Biosciences' score of 0.27 indicating that Prima BioMed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caribou Biosciences 1 Very Positive mention(s) 5 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IMMP or TNYA?

Prima BioMed has higher revenue and earnings than Tenaya Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 1.60 -$53.82M N/A N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.53 N/A

Is IMMP or TNYA more profitable?

Prima BioMed's return on equity of 0.00% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Tenaya Therapeutics N/A -83.75% -66.53%

Does the media refer more to IMMP or TNYA?

In the previous week, Prima BioMed had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for Prima BioMed and 2 mentions for Tenaya Therapeutics. Prima BioMed's average media sentiment score of 0.94 beat Tenaya Therapeutics' score of 0.54 indicating that Prima BioMed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, CBUS or IMMP?

Prima BioMed has higher revenue and earnings than Cibus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cibus $3.64M 29.61 -$127.08M -$1.65 N/A Prima BioMed $16.40M 1.60 -$53.82M N/A N/A

Is CBUS or IMMP more profitable?

Prima BioMed has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Prima BioMed's return on equity of 0.00% beat Cibus' return on equity. Company Net Margins Return on Equity Return on Assets Cibus -2,258.89% -287.03% -27.99% Prima BioMed N/A N/A N/A

Which has preferable valuation and earnings, IMMP or LUCD?

Prima BioMed has higher revenue and earnings than Lucid Diagnostics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prima BioMed $16.40M 1.60 -$53.82M N/A N/A Lucid Diagnostics $4.71M 26.15 -$58.01M -$0.47 N/A

Is IMMP or LUCD more profitable?

Prima BioMed has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%. Company Net Margins Return on Equity Return on Assets Prima BioMed N/A N/A N/A Lucid Diagnostics -959.76% N/A -119.57%

Does the media refer more to IMMP or LUCD?

In the previous week, Prima BioMed had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Prima BioMed and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Prima BioMed's score of 0.94 indicating that Lucid Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prima BioMed 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lucid Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Prima BioMed (IMMP) Competitors

$3.44 -0.13 (-3.64%)

As of 12:57 PM Eastern

Compare

IMMP vs. SPRB, CRBU, TNYA, CBUS, and LUCD

Should you buy Prima BioMed stock or one of its competitors? Prima BioMed's main competitors and comparable companies include Spruce Biosciences (SPRB), Caribou Biosciences (CRBU), Tenaya Therapeutics (TNYA), Cibus (CBUS), and Lucid Diagnostics (LUCD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Prima BioMed compare to Spruce Biosciences?

Prima BioMed (NASDAQ:IMMP) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Prima BioMed's return on equity of 0.00% beat Spruce Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Spruce Biosciences	N/A	-123.53%	-90.35%

Prima BioMed has a beta of 2.27, indicating that its share price is 127% more volatile than the broader market. Comparatively, Spruce Biosciences has a beta of 3.25, indicating that its share price is 225% more volatile than the broader market.

In the previous week, Spruce Biosciences had 1 more articles in the media than Prima BioMed. MarketBeat recorded 4 mentions for Spruce Biosciences and 3 mentions for Prima BioMed. Spruce Biosciences' average media sentiment score of 1.21 beat Prima BioMed's score of 0.94 indicating that Spruce Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Spruce Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 4.3% of Spruce Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Spruce Biosciences has lower revenue, but higher earnings than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	1.60	-$53.82M	N/A	N/A
Spruce Biosciences	$4.91M	23.59	-$38.97M	-$39.78	N/A

Prima BioMed presently has a consensus price target of $110.00, indicating a potential upside of 2,981.23%. Spruce Biosciences has a consensus price target of $158.33, indicating a potential upside of 292.40%. Given Prima BioMed's higher probable upside, equities research analysts plainly believe Prima BioMed is more favorable than Spruce Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Spruce Biosciences	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

Summary

Spruce Biosciences beats Prima BioMed on 9 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Caribou Biosciences?

Caribou Biosciences (NASDAQ:CRBU) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Caribou Biosciences has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

77.5% of Caribou Biosciences shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 8.5% of Caribou Biosciences shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Prima BioMed has higher revenue and earnings than Caribou Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.16M	4.52	-$148.12M	-$1.08	N/A
Prima BioMed	$16.40M	1.60	-$53.82M	N/A	N/A

Caribou Biosciences presently has a consensus target price of $5.50, suggesting a potential upside of 1,070.21%. Prima BioMed has a consensus target price of $110.00, suggesting a potential upside of 2,981.23%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than Caribou Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	1 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.38
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Prima BioMed has a net margin of 0.00% compared to Caribou Biosciences' net margin of -1,030.42%. Prima BioMed's return on equity of 0.00% beat Caribou Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,030.42%	-89.11%	-62.47%
Prima BioMed	N/A	N/A	N/A

In the previous week, Caribou Biosciences had 27 more articles in the media than Prima BioMed. MarketBeat recorded 30 mentions for Caribou Biosciences and 3 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 0.94 beat Caribou Biosciences' score of 0.27 indicating that Prima BioMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caribou Biosciences	1 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Prima BioMed beats Caribou Biosciences on 8 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Tenaya Therapeutics?

Prima BioMed (NASDAQ:IMMP) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends and profitability.

Prima BioMed has a beta of 2.27, suggesting that its share price is 127% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market.

Prima BioMed currently has a consensus price target of $110.00, suggesting a potential upside of 2,981.23%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 667.75%. Given Prima BioMed's higher possible upside, equities analysts plainly believe Prima BioMed is more favorable than Tenaya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Prima BioMed has higher revenue and earnings than Tenaya Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	1.60	-$53.82M	N/A	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.53	N/A

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Prima BioMed had 1 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 3 mentions for Prima BioMed and 2 mentions for Tenaya Therapeutics. Prima BioMed's average media sentiment score of 0.94 beat Tenaya Therapeutics' score of 0.54 indicating that Prima BioMed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed's return on equity of 0.00% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Tenaya Therapeutics	N/A	-83.75%	-66.53%

Summary

Prima BioMed beats Tenaya Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Prima BioMed compare to Cibus?

Cibus (NASDAQ:CBUS) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, media sentiment, analyst recommendations, institutional ownership and profitability.

Cibus currently has a consensus price target of $9.00, indicating a potential upside of 538.30%. Prima BioMed has a consensus price target of $110.00, indicating a potential upside of 2,981.23%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts plainly believe Prima BioMed is more favorable than Cibus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cibus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40

Prima BioMed has higher revenue and earnings than Cibus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cibus	$3.64M	29.61	-$127.08M	-$1.65	N/A
Prima BioMed	$16.40M	1.60	-$53.82M	N/A	N/A

In the previous week, Prima BioMed had 2 more articles in the media than Cibus. MarketBeat recorded 3 mentions for Prima BioMed and 1 mentions for Cibus. Cibus' average media sentiment score of 1.82 beat Prima BioMed's score of 0.94 indicating that Cibus is being referred to more favorably in the media.

Company	Overall Sentiment
Cibus	Very Positive
Prima BioMed	Positive

Prima BioMed has a net margin of 0.00% compared to Cibus' net margin of -2,258.89%. Prima BioMed's return on equity of 0.00% beat Cibus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cibus	-2,258.89%	-287.03%	-27.99%
Prima BioMed	N/A	N/A	N/A

Cibus has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market.

33.8% of Cibus shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 29.9% of Cibus shares are held by company insiders. Comparatively, 3.1% of Prima BioMed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Prima BioMed beats Cibus on 10 of the 14 factors compared between the two stocks.

How does Prima BioMed compare to Lucid Diagnostics?

Prima BioMed (NASDAQ:IMMP) and Lucid Diagnostics (NASDAQ:LUCD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, valuation, profitability, institutional ownership, earnings and analyst recommendations.

Prima BioMed currently has a consensus target price of $110.00, indicating a potential upside of 2,981.23%. Lucid Diagnostics has a consensus target price of $4.19, indicating a potential upside of 591.01%. Given Prima BioMed's higher possible upside, equities analysts clearly believe Prima BioMed is more favorable than Lucid Diagnostics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.40
Lucid Diagnostics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 74.0% of Lucid Diagnostics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by insiders. Comparatively, 6.9% of Lucid Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Prima BioMed has a beta of 2.27, meaning that its share price is 127% more volatile than the broader market. Comparatively, Lucid Diagnostics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Prima BioMed has higher revenue and earnings than Lucid Diagnostics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prima BioMed	$16.40M	1.60	-$53.82M	N/A	N/A
Lucid Diagnostics	$4.71M	26.15	-$58.01M	-$0.47	N/A

In the previous week, Prima BioMed had 1 more articles in the media than Lucid Diagnostics. MarketBeat recorded 3 mentions for Prima BioMed and 2 mentions for Lucid Diagnostics. Lucid Diagnostics' average media sentiment score of 1.13 beat Prima BioMed's score of 0.94 indicating that Lucid Diagnostics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prima BioMed	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lucid Diagnostics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Prima BioMed has a net margin of 0.00% compared to Lucid Diagnostics' net margin of -959.76%.

Company	Net Margins	Return on Equity	Return on Assets
Prima BioMed	N/A	N/A	N/A
Lucid Diagnostics	-959.76%	N/A	-119.57%

Summary

Prima BioMed beats Lucid Diagnostics on 8 of the 14 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMMP vs. The Competition

Export

Metric	Prima BioMed	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$25.35M	$3.89B	$7.27B	$12.97B
Dividend Yield	N/A	3.65%	2.51%	22.89%
P/E Ratio	N/A	12.96	275.40	25.37
Price / Sales	1.55	1,150.23	562.29	78.82
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	0.61	16.59	10.55	5.95
Net Income	-$53.82M	-$22.65M	$3.50B	$380.75M
7 Day Performance	-15.27%	-6.11%	-3.92%	-3.96%
1 Month Performance	-48.05%	-13.89%	-8.30%	-6.81%
1 Year Performance	-91.77%	6.58%	2.35%	-4.58%

Prima BioMed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMMP Prima BioMed	3.1576 of 5 stars	$3.44 -3.6%	$110.00 +3,097.7%	-91.0%	$25.35M	$16.40M	N/A	53	Gap Down
SPRB Spruce Biosciences	3.3259 of 5 stars	$43.99 -3.1%	$158.33 +259.9%	-74.6%	$126.53M	N/A	N/A	8	Positive News
CRBU Caribou Biosciences	3.0028 of 5 stars	$1.18 -1.3%	$7.75 +559.6%	-80.3%	$125.97M	$11.16M	N/A	97	Analyst Revision
TNYA Tenaya Therapeutics	2.4783 of 5 stars	$0.56 -0.9%	$4.00 +615.6%	-73.7%	$125.12M	N/A	N/A	70	News Coverage Gap Down
CBUS Cibus	1.9351 of 5 stars	$1.61 -4.2%	$9.00 +459.0%	-4.1%	$123.05M	$4.35M	N/A	118

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMMP) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Prima BioMed (IMMP) Competitors

IMMP vs. SPRB, CRBU, TNYA, CBUS, and LUCD

How does Prima BioMed compare to Spruce Biosciences?

Summary

How does Prima BioMed compare to Caribou Biosciences?

Summary

How does Prima BioMed compare to Tenaya Therapeutics?

Summary

How does Prima BioMed compare to Cibus?

Summary

How does Prima BioMed compare to Lucid Diagnostics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Prima BioMed (IMMP) Competitors

IMMP vs. SPRB, CRBU, TNYA, CBUS, and LUCD

How does Prima BioMed compare to Spruce Biosciences?

Is IMMP or SPRB more profitable?

Which has more volatility & risk, IMMP or SPRB?

Does the media refer more to IMMP or SPRB?

Do institutionals & insiders believe in IMMP or SPRB?

Which has preferable earnings & valuation, IMMP or SPRB?

Do analysts prefer IMMP or SPRB?

Summary

How does Prima BioMed compare to Caribou Biosciences?

Which has more volatility and risk, CRBU or IMMP?

Do institutionals and insiders hold more shares of CRBU or IMMP?

Which has higher earnings & valuation, CRBU or IMMP?

Do analysts prefer CRBU or IMMP?

Is CRBU or IMMP more profitable?

Does the media prefer CRBU or IMMP?

Summary

How does Prima BioMed compare to Tenaya Therapeutics?

Which has more risk and volatility, IMMP or TNYA?

Do analysts prefer IMMP or TNYA?

Which has preferable earnings and valuation, IMMP or TNYA?

Do insiders & institutionals hold more shares of IMMP or TNYA?

Does the media refer more to IMMP or TNYA?

Is IMMP or TNYA more profitable?

Summary

How does Prima BioMed compare to Cibus?

Do analysts prefer CBUS or IMMP?

Which has better earnings & valuation, CBUS or IMMP?

Does the media favor CBUS or IMMP?

Is CBUS or IMMP more profitable?

Which has more volatility and risk, CBUS or IMMP?

Do institutionals and insiders hold more shares of CBUS or IMMP?

Summary

How does Prima BioMed compare to Lucid Diagnostics?

Do analysts recommend IMMP or LUCD?

Do institutionals & insiders believe in IMMP or LUCD?

Which has more volatility and risk, IMMP or LUCD?

Which has preferable valuation and earnings, IMMP or LUCD?

Does the media refer more to IMMP or LUCD?

Is IMMP or LUCD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMMP vs. The Competition

Prima BioMed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools